Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study

NCT06482086 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06482086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06482086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2021
Completion date
December 1, 2025
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced thyroid gland carcinoma